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Abstract
Background and Objectives: Current studies give us inconsistent results regarding the association of neoplasms and zinc(II)
serum and tissues concentrations. The results of to-date studies using meta-analysis are summarized in this paper.
Methods: Web of Science (Science citation index expanded), PubMed (Medline), Embase and CENTRAL were searched.
Articles were reviewed by two evaluators; quality was assessed by Newcastle-Ottawa scale; meta-analysis was performed
including meta-regression and publication bias analysis.
Results: Analysis was performed on 114 case control, cohort and cross-sectional studies of 22737 participants. Decreased
serum zinc level was found in patients with lung (effect size = 21.04), head and neck (effect size = 21.43), breast (effect
size = 20.93), liver (effect size = 22.29), stomach (effect size = 21.59), and prostate (effect size = 21.36) cancers; elevation
was not proven in any tumor. More specific zinc patterns are evident at tissue level, showing increase in breast cancer tissue
(effect size = 1.80) and decrease in prostatic (effect size = 23.90), liver (effect size = 28.26), lung (effect size = 23.12), and
thyroid cancer (effect size = 22.84). The rest of the included tumors brought ambiguous results, both in serum and tissue
zinc levels across the studies. The association between zinc level and stage or grade of tumor has not been revealed by
meta-regression.
Conclusion: This study provides evidence on cancer-specific tissue zinc level alteration. Although serum zinc decrease was
associated with most tumors mentioned herein, further – prospective - studies are needed.
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Introduction
Zinc(II) plays a role in several intracellular signalling pathways.
It is also a cofactor of numerous enzymes [1]. Its dysregulation is
present in various cancers. Imbalance of zinc transporters causing
intracellular and serum zinc(II) levels alteration was described in
prostate and breast cancers. [2–5]. Questions were raised
whether these associations have clinical applications. Studies
focusing on zinc content in biological materials in cancer patients
provide inconsistent results. Zinc levels in tumor tissues of
prostate [6], liver [7], and lung [8] and its serum levels in breast,
lung, stomach, and prostate cancer patients were reviewed
previously [9].
We investigated the associations of serum and cellular zinc(II)
levels with carcinomas via meta-analysis.
Methods
Literature Search
Search was performed in Web of science (Science citation index
expanded 1945 to April 2013), PubMed (Medline 1968 to April
2013), Embase (1977 to April 2013), and Cochrane Library
(CENTRAL 1953 to April 2013); keywords are shown in Figure 1.
Moreover, cited references of found articles were analyzed.
Selection Criteria
Diagram (Fig. 1) shows acquisition process. Among published
articles, the search was done for clinical trials, case-control and
cohort studies investigating the associations between carcinoma
and tissues and serum zinc levels. Because no difference in zinc(II)
level between serum and plasma was found [10], both materials
were referred as ‘‘serum’’. Studies with full texts available were
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included only. Only the studies where the data were displayed in
the following ways were accepted: (1) sample size, means and
standard deviations, or (2) sample size, means, P values and
statistical test type (one- or two-tailed). If similar data were found
in more studies by the same group, study with most data was
included.
The eligibility of the studies for meta-analysis was evaluated by
J.G. and V.A., discrepancies were discussed with R.K and M.M.
Assessment of Methodological Quality
The quality of studies was assessed by the Newcastle-Ottawa
Scale (NOS) [11]. NOS ranges from 0 to 9 stars. The studies with
,4 stars were excluded, with .6 stars were considered as high
quality; the mean was 5.6 stars.
Main and Subgroup Analyses
First, differences of the serum and tissue zinc levels between
overall tumors and controls were analysed (Table 1). Then,
analyses by tumor type, histology, and methodological quality
were performed (Table 2). To meet conditions of between-study
independence, zinc level was averaged in studies with multiple
tumors, forming age groups or detecting gender separately in case
of the summary. For comparison of individual tumors, the tumor
was taken as a unit of analysis unless violated between-study
independence.
Statistical Analyses
To express the differences in serum and tissue concentrations,
standardized difference in means (Cohen’s d) was used. To assess
heterogeneity across studies, Higgins I2 (describes percentage of
variability) was calculated [12]. Random effects model meta-
analysis was employed when I2.50%; otherwise, fixed model was
used. Publication bias was evaluated using funnel plots and two-
sided Egger tests in groups with .3 studies. Funnel plots of studies
with Egger’s test p,0.05 are asymmetric (Table S1). There was
performed meta-regression using unrestricted maximum likehood
method of studies reporting stage or grade if number of studies
with corresponding moderators was .10 [13,14]. Comprehensive
Meta-analysis Version 2 software (Biostat, Englewood, NJ) was
used for analysis.
Results
Identification of Relevant Studies and their
Characteristics
Total of 3201 articles were found. After excluding articles not
meeting the criteria (Fig. 1) and duplicates, 114 articles studying
130 tumors were included (several studies studied more tumors,
Table S2).
Overall 114 studies including 22737 participants (8584 cases,
14153 controls) were analyzed. From studies reporting age, sex
and ethnicity, the mean age was 54.5612.3 (male) and 49.6612.2
(female); male were included 49.5% and 51.0% in ‘‘tumor’’ and
control groups. Publication date ranged within 1952–2012.
Caucasians, Asians, Hispanics, and Afro-Americans were reported
in 52%, 45%, 1%, and 2%, respectively. Characteristics of studies
are summarized in Table S2. Two clinical, 4 cohort, 6 cross-
sectional, and 102 case control studies were included.
Overall Zinc Level in Sera and Tumors
Serum level. As shown on Fig. 2 and Table 1, serum zinc
level is significantly decreased in patients with tumors (effect
size = 21.08; 95% confidence interval, CI, 21.33 to 20.82) using
random effects model of 58 studies (6223 cases, 10364 controls).
This is consistent with subgroup of 26 high-quality studies (effect
size = 21.30; 95% CI, 21.72 to 20.88). High level of heteroge-
neity is observed (Higgins I2 = 96.71%). Meta-regression did not
reveal that stage, grade, and age or publication year affect effect
size (Table S1). Six studies analyzed serum zinc level in group of
patients with malignant tumor without other specification (516
cases, 3871 controls), and significant decrease was found (Fig. 2)
[15–20].
Tissue level. There was a significant decrease in tissue zinc
level using random effects model meta-analysis of 59 studies (2361
cases, 3789 controls) with effect size 21.44 (CI21.93 to 20.95).
However, publication bias was observed at p = 0.01 and no
significance found in 24 high-quality studies. Meta-regression did
not reveal any moderators to affect global effect size.
Bladder
Significant decrease of serum zinc level was observed (21.24;
95% CI, 21.77 to 20.77) using random effects model of two
studies [21,22] (86 cases, 92 controls); both were ‘‘high-quality’’.
Figure 1. Flow diagram for identification of relevant studies.
doi:10.1371/journal.pone.0099790.g001
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Breast
Serum. There was significant decrease (20.93; 95% CI, 2
1.68 to 20.17) using random effects model meta-analysis of 12
studies (604 cases, 663 controls) [20,23–33] (Fig. 3, Table 1).
However, no significant change was observed in six studies
[20,23,25,27,30,31] and significantly increased level in one [24].
No publication bias was observed (Begg’s funnel plot was
symmetrical, Egger’s 2-tailed test p = 0.086). Subgroup meta-
analysis by methodological quality of study revealed significant
decrease in nine low-quality studies (2 1.32, CI–2.23 to–0.42)
using random effects model, but no significant change in three
high-quality studies using fixed effects model [25,27,31]. With
regard to stage, Yucel et al. found no difference between stages
[33]; in contrary, studies by Gupta et al. and Kuo et al. showed a
decrease in advanced cancer in comparison to early stages [26]
and significantly decreasing trend in relation to stage [29].
Tissue level. Significant elevation was determined using
random effects model of 15 studies (635 cases, 714 controls),
effect size = 1.80 (95% CI, 1.17 to 2.42) [29,34–47]. However, two
studies show insignificant changes [42,46]. The highest levels were
observed in study by Ng et al., which include ductal cancers only
[35]. Publication bias was observed on p = 0.018. Significant
elevation was found in both low- and high- quality studies, while
the levels were higher in 9 high-quality studies (2.33; CI, 1.46 to
3.21). Farquharson et al. reported significantly decreased tissue zinc
concentration in estrogen receptor negative tumors [42]. Kuo et al.
found no trend [29] in relation to grade, while Farquharson et al.
showed significant decrease in grade II-III vs. grade I [42].
Gynecological Tumors (Uterine Corpus, Cervix and
Ovarian)
Serum. Among ovarian and cervical cancers, there was a
significant decrease found (20.39; CI20.60 to 20.17) using fixed
effects model of three studies (164 cases, 171 controls) [20,48,49].
No publication bias was observed. When subgroup meta-analysis
by histological type was done, significant decrease was found in
cervical [48], insignificant changes in ovarian cancer [49]. There
were no significant trends in relation to stage and grade [49].
Tissue level. No significant difference between uterine
corpus and cervix cancers was determined using random-effects
model of 4 studies (80 cases, 123 controls) [37,48,50,51]. No
publication bias was determined. Significant decrease was
reported in two studies [48,51]. Results of high-quality studies
did not show a significant trend.
Digestive System Tumors (Esophageal, Stomach,
Colorectal, Liver, Gallbladder and Pancreatic Carcinoma)
Esophageal, serum. All four studies included in this analysis
(93 cases, 80 controls) [52–55] show significant reduction (22.17;
Table 1. Overall results of meta-analysis by tumor type and statistical model used.
Tumor No. of studies Point estimate 95% CI of point estimate Heterogeneity, I2 Model used
Bladder - serum 2 21.24 21.77 to 20.71 61.74 random
Breast serum 12 20.93 21.68 to 20.17 96.16 random
Breast tissue 15 1.80 1.17 to 2.42 94.89 random
Colorectal serum 5 0.04 22.57 to 2.64 98.98 random
Colorectal tissue 7 0.37 20.97 to 1.72 96.23 random
Esophageal serum 4 22.17 23.23 to 21.11 86.46 random
Esophageal tissue 3 21.57 23.17 to 0.03 94.72 random
Gallbladder - serum 1 22.31 22.96 to 21.65 -
Gallbladder - tissue 2 21.25 21.73 to 20.77 0.00 fixed
Gynecological serum 3 20.39 20.6 to 20.17 49.48 fixed
Gynecological tissue 4 20.70 21.85 to 0.45 91.40 random
Head and neck tissue 2 3.11 25.96 to 12.17 98.75 random
Head Neck serum 5 21.43 22.17 to 20.68 77.46 random
Kidney - tissue 4 22.23 23.89 to 20.57 89.51 random
Liver - serum 3 22.29 25.21 to 0.63 97.64 random
Liver - tissue 7 28.26 211.02 to 25.49 98.49 random
Lung - serum 13 21.04 21.53 to 20.56 92.94 random
Lung - tissue 6 23.12 24.57 to 21.67 96.76 random
Prostate serum 7 21.36 21.97 to 20.75 97.93 random
Prostate tissue 12 23.90 25.26 to 22.54 94.67 random
Stomach serum 4 21.59 23.14 to 20.03 98.24 random
Stomach tissue 3 20.79 21.44 to 20.14 60.85 random
Thyroid serum 3 20.62 23.04 to 1.79 97.69 random
Thyroid tissue 3 22.84 25.39 to 20.29 97.56 random
Overall - serum 58 21.08 21.33 to 20.82 96.71 random
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Table 2. Subgroup analysis by study quality and histological type.
Subgroup Tumor Factor
No. of
studies Point estimate (95% CI) Heterogeneity, I2 Model used
Study quality
Breast serum high 3 0.22 (20.08 to 0.51) 0.00 fixed
Breast serum low 9 21.32 (22.23 to 20.42) 97.06 random
Breast tissue high 9 2.33 (1.46 to 3.21) 95.88 random
Breast tissue low 6 1.11 (0.08 to 2.14) 91.22 random
Colorectal tissue high 2 20.50 (22.84 to 1.85) 81.73 random
Colorectal tissue low 5 0.80 (20.84 to 2.43) 96.55 random
Esophageal serum high 2 21.56 (23.23 to 0.10) 72.04 random
Esophageal serum low 2 22.99 (24.79 to 21.19) 93.50 random
Esophageal tissue high 2 21.60 (23.86 to 0.65) 97.29 random
Esophageal tissue low 1 21.52 (22.56 to 20.47) -
Gynecological tissue high 3 20.14 (21.02 to 0.75) 82.33 random
Gynecological tissue low 1 22.49 (23.31 to 21.66) -
Head Neck serum high 2 20.88 (21.26 to 20.49) 3.16 fixed
Head Neck serum low 3 21.59 (22.08 to 21.10) 86.60 random
Kidney - tissue high 2 21.03 (21.80 to 20.26) 22.30 fixed
Kidney - tissue low 2 23.12 (26.49 to 0.25) 96.07 random
Liver - tissue high 2 28.03 (215.12 to 20.94) 98.00 random
Liver - tissue low 5 212.29 (217.08 to 27.51) 98.84 random
Lung - serum high 7 21.01 (21.69 to 20.33) 95.95 random
Lung - serum low 6 21.09 (21.84 to 20.34) 70.97 random
Prostate serum high 5 22.07 (23.82 to 20.32) 98.59 random
Prostate serum low 2 20.34 (23.07 to 2.39) 78.33 random
Prostate tissue high 3 26.25 (29.71 to 22.78) 98.02 random
Prostate tissue low 9 23.59 (25.34 to 21.85) 92.34 random
Stomach serum high 1 20.13 (20.32 to 0.06) -
Stomach serum low 3 22.09 (24.14 to 20.04) 97.68 random
Stomach tissue high 2 21.14 (21.55 to 20.73) 0.00 fixed
Stomach tissue low 1 20.26 (20.96 to 0.45) -
Overall - serum high 26 21.30 (21.72 to 20.88) 96.62 random
Overall - serum low 32 20.92 (21.3 to 20.54) 96.77 random
Overall - tissue high 23 20.42 (21.23 to 0.38) 97.38 random
Overall - tissue low 36 22.12 (22.77 to 21.47) 96.95 random
Histological type
Gynecological serum Ovary 1 20.07 (20.47 to 0.32) -
Gynecological serum Uterine cervix 1 20.49 (20.77 to 20.21) -
Head Neck serum Larynx 4 21.52 (22.35 to 20.69) 81.96 random
Head Neck serum Oral Cavity 2 20.95 (21.38 to 20.53) 0.00 fixed
Lung - serum adenocarcinoma 2 0.02 (21.49 to 1.54) 95.48 random
Lung - serum large cell 2 20.78 (21.32 to 20.23) 0.00 fixed
Lung - serum NSCLC 4 20.94 (21.36 to 20.53) 58.87 random
Lung - serum small cell 2 21.42 (23.05 to 0.21) 88.46 random
Lung - serum squamous cell 2 21.23 (22.75 to 0.29) 97.01 random
Lung - tissue adenocarcinoma 2 20.89 (22.96 to 1.19) 92.20 random
Lung - tissue large cell 1 21.22 (22.22 to 20.23) -
Lung - tissue NSCLC 2 20.62 (21.88 to 0.65) 88.90 random
Lung - tissue small cell 2 20.52 (20.80 to 20.23) 0.00 fixed
Lung - tissue squamous cell 2 20.48 (22.54 to 1.58) 92.14 random
Thyroid serum folicular 2 21.86 (24.83 to 1.11) 96.81 random
Zinc: Meta-Analysis
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95% CI, 23.23 to 1.11) and it was one of the highest decreases.
Publication bias was identified (p = 0.04) and insignificant decrease
was observed in two high-quality studies.
Esophageal, tissue. No significant change was identified
using meta-analysis of three studies (104 cases, 116 controls)
[52,56,57] due to high variability among studies, even among two
high-quality ones [56,57]. No publication bias was observed.
Stomach, serum. Significant decrease was observed (effect
size = 21.59; 95% CI, 23.14 to 20.03) without publication bias.
However, high variability was present in the four studies (290
cases, 474 controls) [28,30,58,59] and significant decrease was
reported in two studies only [28,59]. No significant change was
observed in one high-quality study [58].
Stomach, tissue. Significant decrease was determined (2
0.79; 95% CI, 21.44 to 20.14) in three studies (71 cases, 67
controls) [37,59,60] and one study showed significant decrease
[59]. No publication bias was identified.
Colorectal cancer, serum. No significant difference was
determined. No study fulfilled criteria of ‘‘high-quality’’. Five
studies were included (313 cases, 216 controls) [28,30,61–63] and
no publication bias was detected. However, two studies showed
significant decrease [28,62], one study showed significant elevation
[61], and thus, high serum zinc level variances were associated
with colorectal cancer. Of studies reporting stage, one showed
significantly decreasing trend on Dukes stage [62], whereas other
showed no significant changes related to TNM stage [61].
Colorectal cancer, tissue. No significant difference was
observed using meta-analysis of seven studies (233 cases, 159
controls) [34,37,46,62,64–66] and no publication bias was
observed. None of the high quality studies revealed significant
differences. One of the largest variation among tissue levels was
observed (effect size = 0.37; 95% CI, 20.97 to 1.72). Two studies
showed significant decrease [62,64] while another two significant
elevation [46,66]. One study including grade did not show
significant trend [64].
Gallbladder, serum. one high-quality study (30 cases, 30
controls), that showed significant decrease, was identified [67].
Gallbladder, tissue. Significant decrease was determined in
two studies [68,69] (39 cases, 40 controls) using fixed effects model





studies Point estimate (95% CI) Heterogeneity, I2 Model used
Thyroid serum papillary 2 21.48 (24.43 to 1.48) 96.38 random
Thyroid tissue folicular 1 0.00 (20.59 to 0.59) -
Thyroid tissue papillary 1 20.50 (21.09 to 0.09) -
Note low is for Newcastle-Ottava scale ,6, high for NOS .6. Random and fixed effect meta-analysis. NSCLC, non-small cell lung cancer, CI, confidence interval.
doi:10.1371/journal.pone.0099790.t002
Figure 2. Level of zinc in sera and tissues by tumor type. Summary of individual meta-analyses. For model used and heterogeneity, see Table 1.
doi:10.1371/journal.pone.0099790.g002
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Liver, serum. No significant change was observed in three
studies [70–72] (149 cases, 121 controls) and no publication bias
was observed. Two high-quality studies [71,72] are in accordance,
showing fixed serum zinc level. One study showed no significant
trend in relation to stage [70].
Liver, tissue. Significant decrease was observed in all 7
studies analysed [70,73–78] (269 cases, 329 controls), effect
size = 28.26 (95% CI, 211.02 to 25.49). Two high-quality
studies [73,76] provided consistent results (28.03; 95% CI, 2
15.12 to 20.93). Publication bias was observed (p = 0.04).
Prostate
Serum. Significant decrease was observed (effect size = 2
1.36; 95% CI, 21.97 to 20.75) using random effects model-meta-
analysis of 7 studies [79–85] (2985 cases, 3539 controls, Fig. 4).
Insignificant changes were observed in large sample studies –
cohort from French SuViMax study (4961 cases and controls) [82]
and Multiethnic Cohort study (1175 cases and controls) [85].
Subgroup meta-analysis found significant decrease in high quality
studies (22.07; 95 CI, 23.82 to 20.32). No publication bias was
observed.
Tissue. Random effects model meta-analysis of 12 studies
(240 cases, 226 controls) [86–97] detected a significant decrease
(effect size = 23.90; 95% CI, 25.26 to 22.54). Only one study
showed insignificant decrease [86]. Most significant decrease was
observed in study by Guntupalli et al. [89]. High level of
publication bias was observed among studies (p = 0.0007). Results
are in agreement with more distinct effect size in high-quality
studies (26.03; 95% CI, 29.39 to 22.67). Trend was not observed
in one study relating to stage and grade [6].
Head and Neck
Serum. Five studies including cancers of oral cavity [98,99]
and larynx [98,100–102] (159 cases, 228 controls) showed
significant decrease (random effects model 21.43; 95% CI, 2
2.17 to 20.68). No publication bias was observed – all studies,
including 2 high-quality ones, showed significant decrease [98,99].
No significant trend was observed between stage and serum zinc
level [100].
Tissue. Two studies (45 cases, 27 controls) [103,104] were
included in the analysis. Findings of these studies were contradic-
tory: one showed significant elevation [103] while the other -
significant decrease [104]. Random effects model did not show
any trend. No significant trend between grade and zinc level was
observed in one study [104].
Thyroid
Serum. No significant difference was observed using random
effects model of three studies (131 cases, 93 controls) [105–107].
One study showed significant elevation [107], the other showed
significant decrease [105] and third, ranked as high quality [106],
found no significant differences. No publication bias was observed.
Subgroup analysis by histological type does not highlight
significant difference between papillary and follicular cancer.
Medullar carcinoma was not included in meta-analysis.
Tissue. Statistically significant decrease was observed using
random effects model (effect size = 22.84; 95% CI, 25.39 to 2
0.29) of three studies (109 cases, 123 controls) [105,108,109].
However, one study reported insignificant results [105], another
included papillary, follicular, medullar cancers and reticulosarco-
ma [108] and the third did not specify histological types. No
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publication bias was present. One study determined no significant
difference between papillary and follicular cancers [105].
Kidney
Tissue. Significant decrease was observed using random
effects model (22.23; 95% CI, 23.89 to 20.57) of 4 studies (66
cases, 45 controls). Results agree with 2 high quality studies
[37,110]. All studies showed significant decrease [37,110–112] and
no publication bias was detected.
Lung
Serum. Significant decrease (21.04; 95% CI, 21.53 to 2
0.56) was identified using random effect model of 13 studies
[20,31,58,113–122] (703 cases, 786 controls, Fig. 5); four of them
showed insignificant changes [20,31,58,115]. No publication bias
was observed (p = 0.38). Analysis of only high-quality studies
provided similar results. Subgroup analysis according to histology
detected significant decrease in non-small cell lung cancer using
random effects model in four studies. Two studies dealt with
histological classification [115,116]: no significant difference was
observed in adenocarcinoma and squamous cell carcinoma using
random effects and significant decrease in large cell carcinoma
using fixed effects (20.78; 95% CI, 21.32 to 20.23). serum zinc
level and stage was analyzed in two studies [114,116]. Klarod et al.
determined significantly lower serum zinc level in advanced
compared to low stages [114]. Similarly, descending trend was
observed between stages T1, T2, and T3 [116]. Negative
correlation between serum zinc level and grade was determined
[116].
Tissue. Significant decrease was determined using random
effects model (23.12; 95% CI, 24.57 to 21.67) of six studies, all
ranked as low-quality [34,46,115,123–125] (470 cases, 1820
controls). However, publication bias was observed (p = 0.03).
Insignificant change was observed in one study [123]. Significant
decrease was determined in small cell lung cancer (20.52; 95%
CI, 20.80 to 20.23) using fixed model and no significant decrease
was identified in non-small cell lung cancer using random effects
model. No significant trend was observed in squamous and
adenocarcinomas. Large cell cancer showed significant decrease in
one study [115].
Discussion
Decreased serum zinc level was found in patients with lung,
head and neck, breast, liver, stomach, and prostate cancers. The
elevation was not proven in any tumor. More specific zinc patterns
are evident in tumors. Unequivocal increase was observed in
breast cancer tissue only and decrease in prostatic, liver, lung, and
thyroid cancer. The rest of the studied tumors brought ambiguous
results, both in serum and tissue zinc levels across the studies. It
cannot be confirmed that the serum zinc level does not change
except of the abovementioned tumors. Serum and tissue zinc level
reduction was evident to certain extent in majority of tumors.
Although insignificant differences were found, the analysis
indicates that none of the tumors clearly disproves that the zinc
levels remained unchanged. Variation of serum zinc level were
found in esophageal cancer patients, in cell zinc content in liver
cancer and both in serum and tissue zinc level in stomach,
colorectal, and thyroid cancers.
Number of studies point to decreasing trend in tumors of higher
grades or stages. Nevertheless, meta-regression could not be
performed on the majority of tumors due to limited number of
studies reporting stage/grade or to inconsistency in the scale used.
Regression analysis of all tumors, however, did not show
dependence on these parameters. Thus, this meta-analysis fails
to explain the sources of high heterogeneity between the studies.
Although serum zinc level decrease in lung, head and neck, and
breast carcinomas was shown by meta-analysis, it is unclear,
whether hypozincaemia is a consequence of tumor, chronic stress
or of a combination of both these effects. Stress, infection or
chronic diseases lead to redistribution of zinc(II) between body
compartments, and thus reduce zincaemia [126]. In addition,
chronic inflammation is a common hallmark of cancer, and thus
might be important mechanism of serum zinc level decrease.
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The association of tissue zinc level and prostate [6], liver [7],
and lung [8] cancers serum zinc level and risk of breast, lung,
stomach, and prostate cancers [9] were in scope of several reviews.
Decrease in prostate cancer tissue zinc level is well-evidenced
[127]. Also review by Zaichick et al. show decrease of zinc in
prostate cancer tissue as compared with benign hyperplasia [6]. A
review by Catalani, focusing on zinc content in lung tumors, is the
only to date meta-analysis. However, its results did not allow
summarizing the significance of tissue metals. No relationship
among tissue zinc level and histotype or stage was found. Zinc
decrease in liver cancer tissues were reviewed by Gurusamy et al.
They declared that meta-analytic approach is impossible because
of heterogeneity of analyzed studies. All mentioned reviews
concluded that there is poor data agreement between studies
determining tissue zinc level. This fact – combined with the low
metal concentrations – calls for the standardization of methods.
Catalani et al. propose standardization of sample collection,
storage, and analysis. Previous reviews were performed only on
specific tumors, with limited number of studies and/or statistic
approaches were missing. Our meta-analytical analysis was done
on all identified carcinomas, serum and tissue levels were analyzed
together, publication bias was assessed and meta-regression was
performed when case sufficient data were present. To reduce
selection and publication biases, prospective cohort study with
defined conditions separating the influence of inflammation is
needed. Interest should be focused on the relation of zinc level in
each histological type, stage, and grade.
There are limitations in this study caused by features of
individual studies: sample sizes, subjects’ characteristics, sampling,
storage and detection methods, and different tumors classification.
Serum zinc level has a limited predictive value, because it is
particularly intracellular ion and it fluctuates in circadian rhythm.
This meta-analysis shows a decrease of zincaemia in lung, head
and neck, and breast carcinoma, increase of tissue zinc in breast
cancer and its decrease in prostate, liver, and lung cancers.
However, this analysis does not provide conclusive data with
regard to stage and grade, and thus does not clarify heterogeneity
in values between the studies.
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